Pharmacogenetics and pharmacogenomics in drug discovery and development: An overview

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 4, 2003, Pages 398-410

  Lindpaintner, Klaus ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug efficacy; Drug safety; Genetics; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ALCOHOL DERIVATIVE; AMINOSALICYLIC ACID; AZATHIOPRINE; BENZOYLCHOLINE; BUTYRYLCHOLINE; CAFFEINE; CAPTOPRIL; CHLORZOXAZONE; COUMARIN; DEBRISOQUINE; DEXTROMETHORPHAN; ERYTHROMYCIN; FLUOROURACIL; ISONIAZID; KETOPROFEN; MEPHENYTOIN; MERCAPTOETHANOL; MERCAPTOPURINE; MIDAZOLAM; MORPHINE; NICOTINE; OMEPRAZOLE; OXAZEPAM; PARAOXON; PENICILLAMINE; SPARTEINE; SULFADIMIDINE; TIOGUANINE; UNINDEXED DRUG; WARFARIN;

BIOMEDICINE; DIFFERENTIAL DIAGNOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FUTUROLOGY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; MEDICAL RESEARCH; MOLECULAR GENETICS; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT;

DRUG DESIGN; GENE EXPRESSION; GENOMICS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 0038397495     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.063     Document Type: Review

References (28)

1. Dickins M, Tucker G: Drug disposition: to phenotype or genotype. Int J Pharm Med 2001; 15:70-3. Also see: http://www.imm.ki.se/CYPalleles/
2. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapies. Science 1999; 206:487-91. Also see: http://www.sciencemag.org/feature/data/1044449.shl/
3. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-6.
4. Dubinsky M, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-13.
5. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-8.
6. Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997; 350:995-9.
7. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-9.
8. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13:25-33.
9. Reihsaus E, Innis M, MacIntyre N and Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8:334-49.
10. Dewar JC, Wheatley AP, Venn A, Morrison JFJ, Britton J, Hall IP. Beta2 adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp All 1998; 28:442-8.
11. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168-70.
12. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997 1; 99:1130-7.
13. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann NY Acad Sci 1999; 884:99-109.
14. Hutchin T, Cortopassi G. Proposed molecular and cellular mechanism for aminoglycoside ototoxicity. Antimicrob Agents Chemother 1994; 38:2517-20.
15. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal anti-body in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14:737-44.
16. Haseltine WA. Not quite pharmacogenomics [letter; comment]. Nat Biotechnol 1998; 16:1295.
17. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest 1998;1 02:1927-32.
18. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-3.
19. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion of the CKR5 structural gene. Science 1996; 273:1856-62.
20. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
21. O'Brien TR, Winkler C, Dean M, Nelson JAE, Carrington M, Michael NL, et al. HIV-1 infection in a man homozygous for CCR5 32. Lancet 1997; 349:1219.
22. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzious C, Seroco Study Group. HIV-1 infection in an individual homozygous for CCR5 32. Lancet 1997; 349: 1219-20.
23. Esteller M, Garcia-Foncillas J, Andion E, Goodman, SN, OF Hidalgo, Vanaclocha V, et al. Inactivation of the DNA-repair gene mgmt and the clinical response of gliomas to alkylating agents. N Engl J Mad 2000; 343:1350-4.
24. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-32.
25. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-2.
26. Roses A. Pharmacogentics and future drug development and delivery. Lancet 2000; 355:1358-61.
27. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Services. http://www.who.int/ncd/hgn/hgnethic.htm
28. Roche Genetics Educational Program. Available upon request from http://www.rochegenetics.com